Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Shares Outstanding (2016 - 2025)

Amicus Therapeutics' Shares Outstanding history spans 16 years, with the latest figure at $310.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 3.95% year-over-year to $310.9 million, compared with a TTM value of $310.9 million through Dec 2025, up 3.95%, and an annual FY2025 reading of $310.9 million, up 3.95% over the prior year.
  • Shares Outstanding for Q4 2025 was $310.9 million at Amicus Therapeutics, up from $308.5 million in the prior quarter.
  • The five-year high for Shares Outstanding was $310.9 million in Q4 2025, with the low at $266.5 million in Q2 2021.
  • Average Shares Outstanding over 5 years is $292.9 million, with a median of $294.9 million recorded in 2023.
  • Year-over-year, Shares Outstanding grew 6.43% in 2021 and then increased 0.79% in 2022.
  • Tracing FOLD's Shares Outstanding over 5 years: stood at $278.9 million in 2021, then increased by 0.79% to $281.1 million in 2022, then rose by 4.44% to $293.6 million in 2023, then grew by 1.86% to $299.0 million in 2024, then rose by 3.95% to $310.9 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Shares Outstanding are $310.9 million (Q4 2025), $308.5 million (Q3 2025), and $308.1 million (Q2 2025).